Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl] -2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), in rodents

Journal of Pharmacology and Experimental Therapeutics

Volumn 321, Issue 3, 2007, Pages 1013-1022

  Fong, Tung M ^a   Guan, Xiao Ming ^a   Marsh, Donald J ^a   Shen, Chun Pyn ^a   Stribling, D Sloan ^a   Rosko, Kim M ^a   Lao, Julie ^a   Yu, Hong ^a   Feng, Yue ^a   Xiao, Jing C ^a   Van Der Ploeg, Lex H T ^a   Goulet, Mark T ^a   Hagmann, Williams K ^a   Lin, Linus S ^a   Lanza Jr , Thomas J ^a   Jewell, James P ^a   Liu, Ping ^a   Shah, Shrenik K ^a   Qi, Hongbo ^a   Tong, Xinchun ^a   Wang, Junying ^a   Xu, Suoyu S ^a   Francis, Barbara ^a   Strack, Alison M ^a   MacIntyre, D Euan ^a   Shearman, Lauren P ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOBESITY AGENT; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; MK 0364; N [3 (4 CHLOROPHENYL) 2 (3 CYANOPHENYL) 1 METHYLPROPYL] 2 METHYL 2 [[5 (TRIFLUOROMETHYL)PYRIDIN 2 YL]OXY]PROPANAMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DOSE RESPONSE; DRUG BINDING; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; FOOD INTAKE; GENE DISRUPTION; HETEROZYGOSITY; HUMAN; HUMAN CELL; MALE; NONHUMAN; OBESITY; PHENOTYPE; PRIORITY JOURNAL; RAT; WEIGHT GAIN;

AMIDES; ANIMALS; ANTI-OBESITY AGENTS; BINDING, COMPETITIVE; BODY TEMPERATURE; BODY WEIGHT; CHO CELLS; CRICETINAE; CRICETULUS; CYCLIC AMP; CYCLOHEXANOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; EATING; FORSKOLIN; HUMANS; INDOLES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOLECULAR STRUCTURE; OBESITY; PIPERIDINES; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; TRANSFECTION;

EID: 34248532300     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.118737     Document Type: Article

References (40)

1. Arnone M, Maruani J, Chaperon F, Thiebot M, Poncelet M, Soubrie P, and Le Fur G (1997) Selective inhibition of sucrose and ethanol intake by SR141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology 132:104-106.
2. Auclair N, Otani S, Soubrie P, and Crepel F (2000) Cannabinoids modulate synaptic strength and plasticity at glutamatergic synapses of rat prefrontal cortex pyramidal neurons. J Neurophysiol 83:3287-3293.
3. Berry EM and Mechoulam R (2002) Tetrahydrocannabinol and endocannabinoids in feeding and appetite. Pharmacol Ther 95:185-190.
4. Berthoud HR (2002) Multiple neural systems controlling food intake and body weight. Neurosci Biobehav Rev 26:393-428.
5. Blundell JE, Jebb SA, Stiubbs RJ, Wilding JR, Lawton CL, Browning L, Whybrow S, and Halford JCG (2006) Effect of rimonabant on energy intake, motivation to eat and body weight with or without hypocaloric diet: the REBA study. Obes Rev 7 (Suppl 2):104.
6. Bouaboula M, Perrachon S, Milligan L, Canat X, Rinaldi-Carmona M, Portier M, Barth F, Calandra B, Pecceu F, Lupker J, et al. (1997) A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J Biol Chem 272:22330-22339.
7. Breivogel CS and Childers SR (1998) The functional neuroanatomy of brain cannabinoid receptors. Neurobiol Dis 5:417-431.
8. Colombo G, Agabio R, Diaz G, Lobina C, Reali R, and Gessa GL (1998) Appetite suppression and weight loss after the cannabinoid antagonist SR141716. Life Sci 63:PL113-PL117.
9. Compton DR, Johnson MR, Melvin LS, and Martin BR (1992) Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents. J Pharmacol Exp Ther 260:201-209.
10. Cota D, Marsicano G, Tschop M, Grubler Y, Flachskamm C, Schubert M, Auer D, Yassouridis A, Thone-Reineke C, Ortmann S, et al. (2003) The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Investig 112:423-431.
11. Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, Fezza F, Miura GI, Palmiter RD, Sugiura T, et al. (2001) Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature (Lond) 410:822-825.
12. Fitton AG and Pertwee RG (1982) Changes in body temperature and oxygen consumption rate of conscious mice produced by intrahypothalamic and intracerebro-ventricular injections of delta 9-tetrahydrocannabinol. Br J Pharmacol 75:409-414.
13. Freedland CS, Poston JS, and Porrino LJ (2000) Effects of SR141716A, a central cannabinoid receptor antagonist, on food-maintained responding. Pharmacol Biochem Behav 67:265-270.
14. Gardner EL and Vorel SR (1998) Cannabinoid transmission and reward-related events. Neurobiol Dis 5:502-533.
15. Gifford AN, Makriyannis A, Volkow ND, and Gatley SJ (2002) In vivo imaging of the brain cannabinoid receptor. Chem Phys Lipids 121:65-72.
16. Greenberg I, Kuehnle J, Medelson J, and Bernstein J (1976) Effects of Marijuana use on body weight and caloric intake in humans. Psychopharmacology 49:79-84.
17. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, et al. (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54:161-202.
18. Ishihara A, Kanatani A, Mashiko S, Tanaka T, Hidaka M, Gomori A, Iwaasa H, Murai N, Egashira S, Murai T, et al. (2006) A neuropeptide Y Y5 antagonist selectively ameliorates body weight gain and associated parameters in dietinduced obese mice. Proc Natl Acad Sci USA 103:7154-7158.
19. Lange JH, Coolen HK, van Stuivenberg HH, Dijksman JA, Herremans AH, Ronken E, Keizer HG, Tipker K, McCreary AC, Veerman W, et al. (2004) Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB(1) cannabinoid receptor antagonists. J Med Chem 47:627-643.
20. Lin LS, Lanza TJ Jr, Jewell JP, Liu P, Shah SK, Qi H, Tong X, Wang J, Xu SS, Fong TM, et al. (2006) Discovery of N-[(1S,2S)-3-(4- chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl) pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity. J Med Chem 49:7584-7587.
21. Liu YL, Connoley IP, Wilson CA, and Stock MJ (2005) Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int J Obes 29:183-187.
22. Martin BR, Stevenson LA, Pertwee RG, Breivogel CS, Williams W, Mahadevan A, and Razdan RK (2002) Agonists and silent antagonists in a series of cannabinoid sulfonamides, in Proceedings of the 12th Annual Symposium on the Cannabinoids; 2002 11-13 July; Pacific Grove, CA. p. 2, International Cannabinoid Research Society, Burlington, VT.
23. Melis M, Pistis M, Perra S, Muntoni AL, Pillolla G, and Gessa GL (2004) Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors. J Neurosci 24:53-62.
24. Need AB, Davis RJ, Alexander-Chacko JT, Eastwood B, Chernet E, Phebus LA, Sindelar DK, and Nomikos GG (2006) The relationship of in vivo central CB1 receptor occupancy to changes in cortical monoamine release and feeding elicited by CB1 receptor antagonists in rats. Psychopharmacology (Berl) 184:26-35.
25. Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Batkai S, Harvey-White J, Mackie K, Offertaler L, Wang L, et al. (2005) Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to dietinduced obesity. J Clin Investig 115:1298-1305.
26. Pertwee RG (2005) Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci 76:1307-1324.
27. Ravinet Trillou C, Delgorge C, Menet C, Arnone M, and Soubrie P (2004) CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to dietinduced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 28:640-648.
28. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Neliat G, Caput D, et al. (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350:240-244.
29. Schlicker E and Kathmann M (2001) Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci 22:565-572.
30. Schwartz MW and Porte DJ (2005) Diabetes, obesity, and the brain. Science (Wash DC) 307:375-379.
31. Seeley RJ and Woods SC (2003) Monitoring of stored and available fuel by the CNS: implications for obesity. Nat Rev Neurosci 4:901-909.
32. Simiand J, Keane M, Keane PE, and Soubrie P (1998) SR141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav Pharmacol 9:179-181.
33. Swanson LW (2005) Anatomy of the soul as reflected in the cerebral hemispheres: neural circuits underlying voluntary control of basic motivated behaviors. J Comp Neurol 493:122-131.
34. Thakur GA, Nikas SP, and Makriyannis A (2005) CB1 cannabinoid receptor ligands. Mini Rev Med Chem 5:631-640.
35. Trojniar W and Wise RA (1991) Facilitory effect of delta9- tetrahydrocannabinol on hypothalamically induced feeding. Psychopharmacology 103:172-176.
36. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S, and RIO Europe Study Group (2005) Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365:1389-1397.
37. Wallmichrath I and Szabo B (2002) Analysis of the effect of cannabinoids on GABAergic neurotransmission in the substantia nigra pars reticulata. Naunyn-Schmiedeberg's Arch Pharmacol 365:326-334.
38. Williams CM and Kirkham TC (2002) Observational analysis of feeding induced by Delta9-THC and anandamide. Physiol Behav 76:241-250.
39. Wilson RI and Nicoll RA (2002) Endocannabinoid signaling in the brain. Science (Wash DC) 296:678-682.
40. Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, and Bonner TI (1999) Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci USA 96:5780-5785.